VERA THERAPEUTICS INC (VERA) Stock Price, Quote, News and Overview
NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD
VERA Quote, Performance and Key Statistics
VERA THERAPEUTICS INC
NASDAQ:VERA (2/4/2025, 8:14:07 PM)
After market: 38.5085 +0.44 (+1.15%)38.07
+1.53 (+4.19%)
The current stock price of VERA is 38.07 USD. In the past month the price decreased by -11.92%. In the past year, price decreased by -11.9%.
VERA Latest News, Press Releases and Analysis
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation...
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
VERA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About VERA
Company Profile
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 82 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The firm is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The firm is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.
Company Info
VERA THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 1200
Brisbane California CALIFORNIA 14623 US
CEO: Marshall Fordyce
Employees: 72
Company Website: https://veratx.com/
Investor Relations: https://ir.veratx.com/
Phone: 16507700077
VERA FAQ
What is the stock price of VERA?
The current stock price of VERA is 38.07 USD.
What is the symbol for VERA THERAPEUTICS INC stock?
The exchange symbol of VERA THERAPEUTICS INC is VERA and it is listed on the Nasdaq exchange.
On which exchange is VERA stock listed?
VERA stock is listed on the Nasdaq exchange.
Is VERA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VERA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VERA.
Does VERA stock pay dividends?
VERA does not pay a dividend.
What is the Price/Earnings (PE) ratio of VERA?
VERA does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.63).
What is the Short Interest ratio of VERA stock?
The outstanding short interest for VERA is 12.52% of its float.
VERA Technical Analysis
VERA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VERA. VERA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VERA Financial Highlights
Over the last trailing twelve months VERA reported a non-GAAP Earnings per Share(EPS) of -2.63. The EPS decreased by 9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.46% | ||
| ROE | -46.49% | ||
| Debt/Equity | 0.17 |
VERA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to VERA. The Buy consensus is the average rating of analysts ratings from 18 analysts.